VIR Vir Biotechnology, Inc.
$10.62▲ +0.38%
Healthcare
Other
After hours
$10.95▲ +3.13%
Sep 11, 7:30 PM ET
Volume 2.08M
Avg Volume (10D) 2.15M
Key Metrics & Fundamentals
Market Cap
$1.80B
P/E Ratio
–
Div Yield
–%
52W Range
4.75 - 11.94
% vs 50 MA
8.38%
% vs 200 MA
22.20%
RSI-14
53.8
MACD Histogram
-0.0600
Beta (1Y vs SPY)
1.75
Free Cash Flow
$123.29M
Gross Rev
$238.94M
Gross Profit
$238.94M
EBITDA
$77.99M
COGS
$0
Operating Exp
$165.47M
Operating Income
$73.47M
EBIT
$73.47M
Pretax Income
$80.26M
Net Income
$80.08M
EPS (Diluted)
0.47
Price & Volume History
Loading chart…
Recent News
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Business Wire · Aug 31, 2026 8:05 PM
Olema Pharmaceuticals Names Jason O'Byrne CFO
MT Newswires · Aug 13, 2026 12:48 PM
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 12, 2026 9:28 PM
Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 6, 2026 12:30 PM
Vir Biotechnology Q2 Earnings Call Highlights
MarketBeat · Aug 6, 2026 7:03 AM
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: 88% HDV Cure Rate and a $1B ...
GuruFocus.com · Aug 6, 2026 5:08 AM
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
Zacks · Aug 6, 2026 12:35 AM
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Business Wire · Aug 5, 2026 8:05 PM
Earnings To Watch: Vir Biotechnology Inc (VIR) Q2 2026 -- GF Value Sees 175% Upside
GuruFocus.com · Aug 4, 2026 1:40 PM
Vir Biotechnology (VIR) Could Be 60% Undervalued On CFO Transition
Simply Wall St. · Aug 1, 2026 12:14 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See VIR's money flow as a full page
Social Sentiment
No Reddit posts found for VIR.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.